2.Kopans DB. Beyond Randomized Controlled Trials. Cancer. 2002;94(2):580-1

References

1. accessed 20 Feb 2017

2.Kopans DB. Beyond randomized controlled trials. Cancer. 2002;94(2):580-1.

3.Surveillance, Epidemiology, and End Results (SEER) Program ( SEER*Stat Database: Mortality - All COD, Aggregated With State, Total U.S. (1969-2014) <Katrina/Rita Population Adjustment>, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released December 2016. Underlying mortality data provided by NCHS (

4.Hellquist BN, Duffy SW, Abdsaleh S, Björneld L, Bordás P, Tabár L, et al. Effectiveness of population-based service screening with mammography for women ages 40 to 49 years: evaluation of the Swedish Mammography Screening in Young Women (SCRY) cohort. Cancer. 2010;117(4):714-22.

5.Saadatmand S, Bretveld R, Siesling S, Tilanus-Linthorst MMA. Influence of tumour stage at breast cancer detection on survival in modern times: population based study in 173 797 patients. BMJ. 2015:h4901.

6.Munoz D, Near AM, van Ravesteyn NT, Lee SJ, Schechter CB, Alagoz O, et al. Effects of Screening and Systemic Adjuvant Therapy on ER-Specific US Breast Cancer Mortality. JNCI Journal of the National Cancer Institute. 2014;106(11):dju289-dju.

7.de Gelder R, Heijnsdijk EAM, Fracheboud J, Draisma G, de Koning HJ. The effects of population-based mammography screening starting between age 40 and 50 in the presence of adjuvant systemic therapy. International Journal of Cancer. 2014;137(1):165-72.

8.Lee CH, Dershaw DD, Kopans D, Evans P, Monsees B, Monticciolo D, et al. Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. J Am Coll Radiol. 2010;7(1):18-27.

9. accessed 05 May 2017

10.Shapiro S. Evaluation of periodic breast cancer screening with mammography. Methodology and early observations. JAMA: The Journal of the American Medical Association. 1966;195(9):731-8.

11.Shapiro S. Evidence on screening for breast cancer from a randomized trial. Cancer. 1977;39(6):2772-82.

12.Tabár L, Gad A, Holmberg LH, Ljungquist U, Fagerberg CJG, Baldetorp L, et al. Reduction in mortality from breast cancer after mass screening with mammography. The Lancet. 1985;325(8433):829-32.

13.Hendrick RE, Smith RA, Rutledge JH, Smart CR. Benefit of Screening Mammography in Women Aged 40-49: A New Meta-Analysis of Randomized Controlled Trials. JNCI Monographs. 1997;1997(22):87-92.

14.Nyström L, Wall S, Rutqvist LE, Lindgren A, Lindqvist M, Rydén S, et al. Breast cancer screening with mammography: overview of Swedish randomised trials. The Lancet. 1993;341(8851):973-8.

15.Larsson L-G, Andersson I, Bjurstam N, Fagerberg G, Frisell J, Tabár L, et al. Updated Overview of the Swedish Randomized Trials on Breast Cancer Screening With Mammography: Age Group 40-49 at Randomization. JNCI Monographs. 1997;1997(22):57-61.

16.Tabár L, Vitak B, Chen TH-H, Yen AM-F, Cohen A, Tot T, et al. Swedish Two-County Trial: Impact of Mammographic Screening on Breast Cancer Mortality during 3 Decades. Radiology. 2011;260(3):658-63.

17.Duffy SW, Tabar L, Smith RA. The Mammographic Screening Trials: Commentary on the Recent Work by Olsen and Gotzsche. CA: A Cancer Journal for Clinicians. 2002;52(2):68-71.

18.Smith RA, Duffy SW, Gabe R, Tabar L, Yen AMF, Chen THH. The randomized trials of breast cancer screening: what have we learned? Radiologic Clinics of North America. 2004;42(5):793-806.

19.Fletcher SW, Black W, Harris R, Rimer BK, Shapiro S. Report of the International Workshop on Screening for Breast Cancer. JNCI Journal of the National Cancer Institute. 1993;85(20):1644-56.

20.Moss SM, Wale C, Smith R, Evans A, Cuckle H, Duffy SW. Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial. The Lancet Oncology. 2015;16(9):1123-32.

21.Bjurstam NG, Björneld LM, Duffy SW. Updated results of the Gothenburg Trial of Mammographic Screening. Cancer. 2016;122(12):1832-5.

22.Tabár L, Yen AM-F, Wu WY-Y, Chen SL-S, Chiu SY-H, Fann JC-Y, et al. Insights from the Breast Cancer Screening Trials: How Screening Affects the Natural History of Breast Cancer and Implications for Evaluating Service Screening Programs. The Breast Journal. 2014;21(1):13-20.

23.Feig SA. Screening mammography benefit controversies: sorting the evidence. Radiol Clin North Am. 2014;52(3):455-80.

24.Alexander FE, Anderson TJ, Brown HK, Forrest APM, Hepburn W, Kirkpatrick AE, et al. 14 years of follow-up from the Edinburgh randomised trial of breast-cancer screening. The Lancet. 1999;353(9168):1903-8.

25.Baines CJ, Miller AB, Kopans DB, Moskowitz M, Sanders DE, Sickles EA, et al. Canadian National Breast Screening Study: assessment of technical quality by external review. American Journal of Roentgenology. 1990;155(4):743-7.

26.Kopans DB. The Canadian Screening Program: A Different Perspective. American Journal of Roentgenology. 1990;155(4):748-9.

27.Boyd NF, Jong RA, Yaffe MJ, Tritchler D, Lockwood G, Zylak CJ. A critical appraisal of the Canadian National Breast Cancer Screening Study. Radiology. 1993;189(3):661-3.

28.Kopans DB, Feig SA. The Canadian National Breast Screening Study: a critical review. American Journal of Roentgenology. 1993;161(4):755-60.

29.Kopans DB. An open letter to panels that are deciding guidelines for breast cancer screening. Breast Cancer Research and Treatment. 2015;151(1):19-25.

30.Bailar JC, 3rd, MacMahon B. Randomization in the Canadian National Breast Screening Study: a review for evidence of subversion. CMAJ. 1997;156(2):193-9.

31.Tarone RE. The excess of patients with advanced breast cancer in young women screened with mammography in the Canadian National Breast Screening Study. Cancer. 1995;75(4):997-1003.

32.Tabar L, Duffy SW, Yen MF, Warwick J, Vitak B, Chen HH, et al. All-cause mortality among breast cancer patients in a screening trial: support for breast cancer mortality as an end point. Journal of Medical Screening. 2002;9(4):159-62.

33.Fletcher SW. Breast Cancer Screening Among Women in Their Forties: An Overview of the Issues. JNCI Monographs. 1997;1997(22):5-9.

34.Koning HJd, Boer R, Warmerdam PG, Beemsterboer PMM, van PJdM. Quantitative Interpretation of Age-Specific Mortality Reductions From the Swedish Breast Cancer-Screening Trials. JNCI Journal of the National Cancer Institute. 1995;87(16):1217-23.

35.Kopans DB. Informed decision making: age of 50 is arbitrary and has no demonstrated influence on breast cancer screening in women. AJR Am J Roentgenol. 2005;185(1):177-82.

36.Broeders M, Moss S, Nyström L, Njor S, Jonsson H, Paap E, et al. The Impact of Mammographic Screening on Breast Cancer Mortality in Europe: A Review of Observational Studies. Journal of Medical Screening. 2012;19(1_suppl):14-25.

37.Nickson C, Mason KE, English DR, Kavanagh AM. Mammographic Screening and Breast Cancer Mortality: A Case-Control Study and Meta-analysis. Cancer Epidemiology Biomarkers & Prevention. 2012;21(9):1479-88.

38.Coldman A, Phillips N, Wilson C, Decker K, Chiarelli AM, Brisson J, et al. Pan-Canadian Study of Mammography Screening and Mortality from Breast Cancer. JNCI Journal of the National Cancer Institute. 2014;106(11):dju261-dju.

39.Mandelblatt JS, Cronin KA, Bailey S, Berry DA, de Koning HJ, Draisma G, et al. Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms. Ann Intern Med. 2009;151(10):738-47.

40.Mandelblatt JS CK dKH, Miglioretti DL, Schecter CS, Stout N. Model Report: Collaborative Modeling of U.S. Breast Cancer Screening Strategies. . In: Force USPST, editor. Rockville, MD: AHRQ Publication No. 14-05201 EF-4. ; 2015.

41.Mandelblatt JS, Stout NK, Schechter CB, van den Broek JJ, Miglioretti DL, Krapcho M, et al. Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies. Ann Intern Med. 2016;164(4):215-25.

42.Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine. 2009;151(10):716.

43.Siu AL. Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine. 2016;164(4):279.

44.Hendrick RE, Helvie MA. United States Preventive Services Task Force Screening Mammography Recommendations: Science Ignored. American Journal of Roentgenology. 2011;196(2):W112-W6.

45.Hendrick RE, Helvie MA. Mammography Screening: A New Estimate of Number Needed to Screen to Prevent One Breast Cancer Death. American Journal of Roentgenology. 2012;198(3):723-8.

46.Arleo EK, Hendrick RE, Helvie MA, Sickles EA. Comparison of recommendations for screening mammography using CISNET models. . Cancer. 2017;in press.

47.Shulman LN, Willett W, Sievers A, Knaul FM. Breast Cancer in Developing Countries: Opportunities for Improved Survival. Journal of Oncology. 2010;2010:1-6.

48.Helvie MA, Chang JT, Hendrick RE, Banerjee M. Reduction in late-stage breast cancer incidence in the mammography era: Implications for overdiagnosis of invasive cancer. Cancer. 2014;120(17):2649-56.

49.Chu KC, Smart CR, Tarone RE. Analysis of Breast Cancer Mortality and Stage Distribution by Age for the Health Insurance Plan Clinical Trial. JNCI Journal of the National Cancer Institute. 1988;80(14):1125-32.

50.Elkin EB, Hudis C, Begg CB, Schrag D. The effect of changes in tumor size on breast carcinoma survival in the U.S.: 1975-1999. Cancer. 2005;104(6):1149-57.

51.Narod SA. Tumour size predicts long-term survival among women with lymph node-positive breast cancer. Curr Oncol. 2012;19(5):249-53.

52.Barth RJ, Gibson GR, Carney PA, Mott LA, Becher RD, Poplack SP. Detection of Breast Cancer on Screening Mammography Allows Patients to Be Treated with Less-Toxic Therapy. American Journal of Roentgenology. 2005;184(1):324-9.

53.Coldman AJ, Phillips N, Speers C. A retrospective study of the effect of participation in screening mammography on the use of chemotherapy and breast conserving surgery. International Journal of Cancer. 2007;120(10):2185-90.

54.Malmgren JA, Parikh J, Atwood MK, Kaplan HG. Impact of Mammography Detection on the Course of Breast Cancer in Women Aged 40–49 Years. Radiology. 2012;262(3):797-806.

55.Malmgren JA, Parikh J, Atwood MK, Kaplan HG. Improved Prognosis of Women Aged 75 and Older with Mammography-detected Breast Cancer. Radiology. 2014;273(3):686-94.

56.Spillane AJ, Kennedy CW, Gillett DJ, Carmalt HL, Janu NC, Rickard MT, et al. Screen-detected breast cancer compared to symptomatic presentation: An analysis of surgical treatment and end-points of effective mammographic screening. ANZ Journal of Surgery. 2001;71(7):398-402.

57.Zorzi M, Puliti D, Vettorazzi M, De Lisi V, Falcini F, Federico M, et al. Mastectomy rates are decreasing in the era of service screening: a population-based study in Italy (1997–2001). British Journal of Cancer. 2006;95(9):1265-8.

58.Geiger AM. A Population-Based Study of Bilateral Prophylactic Mastectomy Efficacy in Women at Elevated Risk for Breast Cancer in Community Practices. Archives of Internal Medicine. 2005;165(5):516.

59.Hartmann LC, Schaid DJ, Woods JE, Crotty TP, Myers JL, Arnold PG, et al. Efficacy of Bilateral Prophylactic Mastectomy in Women with a Family History of Breast Cancer. New England Journal of Medicine. 1999;340(2):77-84.

60.Moyer VA. Medications for Risk Reduction of Primary Breast Cancer in Women: U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine. 2013.

61.Nelson HD, Smith MEB, Griffin JC, Fu R. Use of Medications to Reduce Risk for Primary Breast Cancer: A Systematic Review for the U.S. Preventive Services Task Force. Annals of Internal Medicine. 2013;158(8):604.

62.Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, et al. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. N Engl J Med. 2016;375(3):209-19.

63.Rosenberg RD, Yankaskas BC, Abraham LA, Sickles EA, Lehman CD, Geller BM, et al. Performance Benchmarks for Screening Mammography. Radiology. 2006;241(1):55-66.

64.Lee CS, Bhargavan-Chatfield M, Burnside ES, Nagy P, Sickles EA. The National Mammography Database: Preliminary Data. American Journal of Roentgenology. 2016;206(4):883-90.

65.Lehman CD, Arao RF, Sprague BL, Lee JM, Buist DSM, Kerlikowske K, et al. National Performance Benchmarks for Modern Screening Digital Mammography: Update from the Breast Cancer Surveillance Consortium. Radiology. 2017;283(1):49-58.

66.Lee CS, Sengupta D, Bhargavan-Chatfield M, Sickles EA, Burnside ES, Zuley ML. Association of Patient Age With Outcomes of Current-Era, Large-Scale Screening Mammography: Analysis of Data From the National Mammography Database. JAMA Oncol. 2017.

67.Grabler P, Sighoko D, Wang L, Allgood K, Ansell D. Recall and Cancer Detection Rates for Screening Mammography: Finding the Sweet Spot. AJR Am J Roentgenol. 2017;208(1):208-13.

68.Blanchard K, Colbert JA, Kopans DB, Moore R, Halpern EF, Hughes KS, et al. Long-term risk of false-positive screening results and subsequent biopsy as a function of mammography use. Radiology. 2006;240(2):335-42.

69.Gram IT, Lund E, Slenker SE. Quality of life following a false positive mammogram. British Journal of Cancer. 1990;62(6):1018-22.

70.Lerman C, Trock B, Rimer BK, Boyce A, Jepson C, Engstrom PF. Psychological and behavioral implications of abnormal mammograms. Ann Intern Med. 1991;114(8):657-61.

71.Sutton S, Saidi G, Bickler G, Hunter J. Does routine screening for breast cancer raise anxiety? Results from a three wave prospective study in England. Journal of Epidemiology & Community Health. 1995;49(4):413-8.

72.Scaf-Klomp W, Sanderman R, van de Wiel HB, Otter R, van den Heuvel WJ. Distressed or relieved? Psychological side effects of breast cancer screening in The Netherlands. Journal of Epidemiology & Community Health. 1997;51(6):705-10.

73.Gilbert FJ, Cordiner CM, Affleck IR, Hood DB, Mathieson D, Walker LG. Breast screening: the psychological sequelae of false- positive recall in women with and without a family history of breast cancer. European Journal of Cancer. 1998;34(13):2010-4.

74.Meystre-Agustoni G, Paccaud F, Jeannin A, Dubois-Arber F. Anxiety in a cohort of Swiss women participating in a mammographic screening programme. Journal of Medical Screening. 2001;8(4):213-9.

75.Mainiero MB, Schepps B, Clements NC, Bird CE. Mammography-related anxiety: effect of preprocedural patient education. Women's Health Issues. 2001;11(2):110-5.

76.Lampic C, Thurfjell E, Bergh J, Sjödén PO. Short- and long-term anxiety and depression in women recalled after breast cancer screening. European Journal of Cancer. 2001;37(4):463-9.

77.Heckman BD, Fisher EB, Monsees B, Merbaum M, Ristvedt S, Bishop C. Coping and Anxiety in Women Recalled for Additional Diagnostic Procedures Following an Abnormal Screening Mammogram. Health Psychology. 2004;23(1):42-8.

78.Barton MB, Morley DS, Moore S, Allen JD, Kleinman KP, Emmons KM, et al. Decreasing Women's Anxieties After Abnormal Mammograms: A Controlled Trial. JNCI Journal of the National Cancer Institute. 2004;96(7):529-38.

79.Yasunaga H, Ide H, Imamura T, Ohe K. Women’s Anxieties Caused by False Positives in Mammography Screening: A Contingent Valuation Survey. Breast Cancer Research and Treatment. 2006;101(1):59-64.

80.Aro AR, Pilvikki Absetz S, van Elderen TM, van der Ploeg E, van der Kamp LJT. False-positive findings in mammography screening induces short-term distress— breast cancer-specific concern prevails longer. European Journal of Cancer. 2000;36(9):1089-97.

81.Haas J, Kaplan C, McMillan A, Esserman LJ. Does Timely Assessment Affect the Anxiety Associated with an Abnormal Mammogram Result? Journal of Women's Health & Gender-Based Medicine. 2001;10(6):599-605.

82.Brett J, Austoker J. Women who are recalled for further investigation for breast screening: psychological consequences 3 years after recall and factors affecting re-attendance. Journal of Public Health. 2001;23(4):292-300.

83.Lampic C, Thurfjell E, Sjödén PO. The influence of a false-positive mammogram on a woman's subsequent behaviour for detecting breast cancer. European Journal of Cancer. 2003;39(12):1730-7.

84.Tosteson ANA, Fryback DG, Hammond CS, Hanna LG, Grove MR, Brown M, et al. Consequences of False-Positive Screening Mammograms. JAMA Internal Medicine. 2014;174(6):954.

85.Chiarelli AM, Muradali D, Blackmore KM, Smith CR, Mirea L, Majpruz V, et al. Evaluating wait times from screening to breast cancer diagnosis among women undergoing organised assessment vs usual care. British Journal of Cancer. 2017.

86.Hislop TG, Harris SR, Jackson J, Thorne SE, Rousseau EJ, Coldman AJ, et al. Satisfaction and Anxiety for Women During Investigation of an Abnormal Screening Mammogram. Breast Cancer Research and Treatment. 2002;76(3):245-54.

87.Ganott MA, Sumkin JH, King JL, Klym AH, Catullo VJ, Cohen CS, et al. Screening Mammography: Do Women Prefer a Higher Recall Rate Given the Possibility of Earlier Detection of Cancer? Radiology. 2006;238(3):793-800.

88.Pencina MJ, Navar-Boggan AM, D'Agostino RB, Williams K, Neely B, Sniderman AD, et al. Application of New Cholesterol Guidelines to a Population-Based Sample. New England Journal of Medicine. 2014;370(15):1422-31.

89.Puliti D, Duffy SW, Miccinesi G, De Koning H, Lynge E, Zappa M, et al. Overdiagnosis in Mammographic Screening for Breast Cancer in Europe: A Literature Review. Journal of Medical Screening. 2012;19(1_suppl):42-56.

90.Marmot MG, Altman DG, Cameron DA, Dewar JA, Thompson SG, Wilcox M. The benefits and harms of breast cancer screening: an independent review. British Journal of Cancer. 2013;108(11):2205-40.

91.Oeffinger KC, Fontham ETH, Etzioni R, Herzig A, Michaelson JS, Shih Y-CT, et al. Breast Cancer Screening for Women at Average Risk. JAMA. 2015;314(15):1599.

92.Zackrisson S, Andersson I, Janzon L, Manjer J, Garne JP. Rate of over-diagnosis of breast cancer 15 years after end of Malmo mammographic screening trial: follow-up study. BMJ. 2006;332(7543):689-92.

93.Gunsoy NB, Garcia-Closas M, Moss SM. Modelling the overdiagnosis of breast cancer due to mammography screening in women aged 40 to 49 in the United Kingdom. Breast Cancer Research. 2012;14(6):R152.

94.Hellquist BN, Duffy SW, Nyström L, Jonsson H. Overdiagnosis in the population-based service screening programme with mammography for women aged 40 to 49 years in Sweden. Journal of Medical Screening. 2012;19(1):14-9.

95.Bleyer A, Welch HG. Effect of Three Decades of Screening Mammography on Breast-Cancer Incidence. New England Journal of Medicine. 2012;367(21):1998-2005.

96.Welch HG, Prorok PC, O’Malley AJ, Kramer BS. Breast-Cancer Tumor Size, Overdiagnosis, and Mammography Screening Effectiveness. New England Journal of Medicine. 2016;375(15):1438-47.

97.Kopans DB. Arguments Against Mammography Screening Continue to be Based on Faulty Science. The Oncologist. 2014;19(2):107-12.

98.Duffy SW, Dibden A, Michalopoulos D, Offman J, Parmar D, Jenkins J, et al. Screen detection of ductal carcinoma in situ and subsequent incidence of invasive interval breast cancers: a retrospective population-based study. The Lancet Oncology. 2016;17(1):109-14.

99.Puliti D, Bucchi L, Mancini S, Paci E, Baracco S, Campari C, et al. Advanced breast cancer rates in the epoch of service screening: The 400,000 women cohort study from Italy. European Journal of Cancer. 2017;75:109-16.

100.Garfinkel L, Boring CC, Heath CW. Changing trends: An overview of breast cancer incidence and mortality. Cancer. 1994;74(S1):222-7.

101.Bennett RL, Sellars SJ, Moss SM. Interval cancers in the NHS breast cancer screening programme in England, Wales and Northern Ireland. British Journal of Cancer. 2011;104(4):571-7.

102.Nederend J, Duijm LEM, Voogd AC, Groenewoud JH, Jansen FH, Louwman MWJ. Trends in incidence and detection of advanced breast cancer at biennial screening mammography in The Netherlands: a population based study. Breast Cancer Research. 2012;14(1).

103.Gilliland FD. Biologic Characteristics of Interval and Screen-Detected Breast Cancers. Journal of the National Cancer Institute. 2000;92(9):743-9.

104.Porter PL, El-Bastawissi AY, Mandelson MT, Lin MG, Khalid N, Watney EA, et al. Breast Tumor Characteristics as Predictors of Mammographic Detection: Comparison of Interval- and Screen-Detected Cancers. JNCI Journal of the National Cancer Institute. 1999;91(23):2020-8.

105.Domingo L, Blanch J, Servitja S, Corominas JM, Murta-Nascimento C, Rueda A, et al. Aggressiveness features and outcomes of true interval cancers. European Journal of Cancer Prevention. 2013;22(1):21-8.

106.Strand F, Humphreys K, Cheddad A, Törnberg S, Azavedo E, Shepherd J, et al. Novel mammographic image features differentiate between interval and screen-detected breast cancer: a case-case study. Breast Cancer Research. 2016;18(1).

107.Henderson LM, O'Meara ES, Braithwaite D, Onega T. Performance of digital screening mammography among older women in the United States. Cancer. 2014;121(9):1379-86.

108.Vyas A, Madhavan S, Sambamoorthi U. Association between persistence with mammography screening and stage at diagnosis among elderly women diagnosed with breast cancer. Breast Cancer Research and Treatment. 2014;148(3):645-54.

109.Badgwell BD, Giordano SH, Duan ZZ, Fang S, Bedrosian I, Kuerer HM, et al. Mammography Before Diagnosis Among Women Age 80 Years and Older With Breast Cancer. Journal of Clinical Oncology. 2008;26(15):2482-8.

110.McCarthy EP, Burns RB, Freund KM, Ash AS, Shwartz M, Marwill SL, et al. Mammography Use, Breast Cancer Stage at Diagnosis, and Survival Among Older Women. Journal of the American Geriatrics Society. 2000;48(10):1226-33.

111.Vacek PM, Skelly JM. A Prospective Study of the Use and Effects of Screening Mammography in Women Aged 70 and Older. Journal of the American Geriatrics Society. 2014;63(1):1-7.

112.McPherson CP, Swenson KK, Lee MW. The Effects of Mammographic Detection and Comorbidity on the Survival of Older Women with Breast Cancer. Journal of the American Geriatrics Society. 2002;50(6):1061-8.

113.Dijck JV, Verbeek AL, Beex LV, Hendriks JH, Holland R, Mravunac M, et al. Breast-cancer mortality in a non-randomized trial on mammographic screening in women over age 65. International journal of cancer. 1997;70(2):164-8.

114.Lee SJ, Boscardin WJ, Stijacic-Cenzer I, Conell-Price J, O'Brien S, Walter LC. Time lag to benefit after screening for breast and colorectal cancer: meta-analysis of survival data from the United States, Sweden, United Kingdom, and Denmark. BMJ. 2012;346(jan08 12):e8441-e.

115.Mainiero MB, Lourenco A, Mahoney MC, Newell MS, Bailey L, Barke LD, et al. ACR Appropriateness Criteria Breast Cancer Screening. Journal of the American College of Radiology. 2016;13(11):R45-R9.

116.Bernardi D, Caumo F, Macaskill P, Ciatto S, Pellegrini M, Brunelli S, et al. Effect of integrating 3D-mammography (digital breast tomosynthesis) with 2D-mammography on radiologists’ true-positive and false-positive detection in a population breast screening trial. European Journal of Cancer. 2014;50(7):1232-8.

117.Bernardi D, Ciatto S, Pellegrini M, Anesi V, Burlon S, Cauli E, et al. Application of breast tomosynthesis in screening: incremental effect on mammography acquisition and reading time. The British Journal of Radiology. 2012;85(1020):e1174-e8.

118.Caumo F, Bernardi D, Ciatto S, Macaskill P, Pellegrini M, Brunelli S, et al. Incremental effect from integrating 3D-mammography (tomosynthesis) with 2D-mammography: Increased breast cancer detection evident for screening centres in a population-based trial. The Breast. 2014;23(1):76-80.